What "we stick around" means: sipra's post-prescription support promise

A man fills out an online form, has a three-minute call, and a box of medication shows up a week later. He starts the shots. By week four he feels unwell and is not sure if that is expected or a reason to stop. He logs back in to ask. There is no one there. No message thread, no nurse line, no follow-up appointment, just a renewal date and a charge that keeps coming. He is holding a real prescription and standing completely alone with it. That gap, the silence after the box arrives, is the thing we built sipra to close.

The short answer: "we stick around" means the care does not end when the prescription ships. Good treatment with GLP-1 medication or hormone therapy needs dose adjustments, side-effect help, periodic lab checks, and a clear bill you can read. A provider who disappears after writing the script is not finished with the job. They left in the middle of it.

What you'll learn

• What the "post-prescription support gap" is, and why it now has a name
• What ongoing care should actually include, in plain terms
• Why follow-up and dose titration are not optional extras
• When lab monitoring matters, and what gets checked
• What honest billing looks like, and what to watch for
• A short list of things to demand from any provider, sipra included

There is a pattern in direct-to-consumer telehealth that has become common enough to have a name. You answer a questionnaire, maybe have a brief video or phone visit, and a prescription is issued. Then the relationship goes quiet. The medication keeps arriving and the card keeps getting charged, but the clinical part, the part where someone is actually watching how you are doing, never really starts.

This is not just a complaint posted to a forum. A 2026 News and Perspectives article in the Journal of Medical Internet Research is titled "After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care." In it, one person describes a spouse who had been on GLP-1 therapy through a telehealth platform for three years with no contact with a provider beyond a three-minute call when the medication was first ordered ¹.

Why does it happen? The prescribe-and-disappear model is cheaper to run. A questionnaire and a quick visit can be heavily automated. Real follow-up, with people who answer messages and clinicians who adjust doses, costs money and does not scale as neatly. So some services optimize for the part that is easy to sell, the prescription, and quietly skip the part that is hard to staff, the support.

So when we say "we stick around," we are pointing straight at this gap. It is the whole reason the phrase exists.

Strip away the marketing language and ongoing care is a short, concrete list. For the categories sipra works in, GLP-1 weight treatment and hormone therapy among them, it looks like this:

• A way to reach a clinician between visits. Not a chatbot that closes the ticket. A message thread where a real person reads what you wrote and answers.
• Dose adjustments based on how you are doing. Your starting dose is a starting point, not a verdict.
• Side-effect help. A clinician who can tell you whether what you are feeling is expected or a reason to pause.
• Lab work at the right intervals. Baseline before you start, then checks on a schedule that fits the medication.
• A plan for stopping. Including how to taper if and when that is appropriate.
• Billing you can actually understand. Every charge explained before it happens.

None of this is exotic. It is ordinary good medicine, the kind you would expect from a clinic you walk into. The only thing notable about it is how often the online version leaves it out.

With GLP-1 medications like semaglutide (Wegovy®), the dose is increased gradually. The Wegovy® injection label starts at 0.25 mg once weekly and steps up every 4 weeks toward the maintenance dose, and it says to follow that schedule to reduce the risk of gastrointestinal adverse reactions ². This is called titration, and it is not a formality.

The label also says that if a dose is not tolerated during escalation, the next increase can be delayed for 4 weeks ². That is a clinical decision. Talk to your clinician about how the ramp is going, and let them decide whether to hold, delay, or adjust your dose.

Notice what that requires: a clinician who knows how you are doing right now. None of it works if no one is paying attention. This is the mechanical reason the support gap matters so much. Titration is the part of GLP-1 care most likely to go wrong without follow-up, and it is also the part a prescribe-and-disappear model is least equipped to handle. Individual results vary, and how a given person tolerates the ramp varies too, which is exactly why a fixed schedule mailed to your door is not the same as care.

Hormone therapy makes the case for monitoring even more plainly. Responsible hormone care does not start without current lab data, and it does not run on autopilot after that.

For men on testosterone, the Endocrine Society's clinical practice guideline calls for a standardized monitoring plan: checking symptoms and adverse effects, measuring testosterone and hematocrit, and evaluating prostate cancer risk during the first year of treatment ³. For women with a uterus who take estrogen, a progestogen is usually part of the plan to protect the uterine lining, and unexpected bleeding is something to report to your clinician.

The pattern is the same across both: baseline labs before starting, then follow-up on a schedule your clinician sets. A provider who prescribes hormones without a recent lab and never asks for another one is not monitoring you. They are guessing, and asking you to guess along with them.

The support gap has a financial twin. The same model that goes quiet on the clinical side often gets very loud on the billing side, with charges that are hard to predict and subscriptions that are hard to leave.

The Federal Trade Commission reported in October 2024 that it was receiving nearly 70 consumer complaints a day about recurring charges and hard-to-cancel subscriptions, up from 42 a day in 2021 ⁴. The principle behind the FTC's negative-option work is simple and worth holding any provider to: the material terms, including the full cost, should be disclosed clearly before you hand over your payment information, and canceling should be as easy as signing up was.

That is the standard we hold ourselves to. Full cost disclosed before checkout, not discovered later on a statement. Nothing is charged until a physician approves your treatment. No charge lands without you knowing what it is for. And leaving is a button, not a phone call you have to win an argument to end. Honest billing is part of staying around. A bill you cannot read is its own kind of disappearing.

Is your current provider actually sticking around?

Ask yourself two questions:

1. When did a clinician last adjust your dose or review your labs?
2. If you messaged them today about a side effect, who would answer: a clinician who knows your case, a bot, or no one?

If the honest answers are "never" and "not sure," you may be in the gap this article is about.

Put the two models side by side and the difference stops being abstract.

This is not a claim that supported care guarantees a particular result. It does not, and individual results vary. It is a claim about what care should consist of, regardless of who is delivering it.

We named the brand promise "we stick around" before we wrote a word of this, because the gap above is the problem we set out to solve. sipra connects you with licensed US physicians for GLP-1 weight treatment and other therapy categories, and the part we care about most is everything that happens after the prescription: the follow-up, the dose adjustments, the lab checks, the message that gets answered, the bill you can read.

But we would rather you treat this as a standard than a sales pitch. The list in this article is the one to hold up against any provider you consider, ours included. If a service cannot show you how it handles titration, when it checks your labs, how you reach a clinician, and exactly what you will be charged, that tells you something before you ever sign up. Take control of your health by asking those questions out loud and waiting for real answers.

The silence after the box arrives is avoidable. You just have to know to look for it before you sign up, not after.

1. Ask who answers. Before you pay, find out exactly how you reach a clinician between visits.
2. Ask about labs and dose changes. A provider who cannot describe their monitoring schedule and their plan for adjusting your dose has not planned to do it.
3. Read the full cost out loud. Make the total price and the cancellation steps appear before you enter a card. If they will not, that is your answer.

We built sipra so the answers to all three are easy to find. We stick around. Take control of your health.